Changes in bone metabolic parameters following oral calcium supplementation in an adult patient with vitamin D-dependent rickets type 2A

Endocrine Journal

Volumn 64, Issue 6, 2017, Pages 589-596

  Kinoshita, Yuka ^a   Ito, Nobuaki ^a   Makita, Noriko ^a   Nangaku, Masaomi ^a   Fukumoto, Seiji ^b  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Calcium; Hyperparathyroidism; Rickets; Vitamin D receptor

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM LACTATE; GENOMIC DNA; MESSENGER RNA; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; VDR PROTEIN, HUMAN;

ADULT; ALOPECIA; ARTICLE; BONE METABOLISM; BONE TURNOVER; CASE REPORT; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE INCREASE; FEMALE; GENE; GENETIC ANALYSIS; HUMAN; METABOLIC PARAMETERS; MONOTHERAPY; REAL TIME POLYMERASE CHAIN REACTION; RICKETS; SECONDARY HYPERPARATHYROIDISM; STOP CODON; VITAMIN D DEPENDENT RICKETS TYPE 2A; VITAMIN D RECEPTOR GENE; YOUNG ADULT; BONE; CALCIUM INTAKE; DIET THERAPY; DIETARY SUPPLEMENT; FAMILIAL HYPOPHOSPHATEMIC RICKETS; GENETICS; METABOLISM; MUTATION; PATHOPHYSIOLOGY; THERAPEUTIC USE; TREATMENT OUTCOME;

ADULT; ALOPECIA; BONE AND BONES; CALCIUM, DIETARY; CODON, TERMINATOR; DIETARY SUPPLEMENTS; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MUTATION; RECEPTORS, CALCITRIOL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85021739049     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ16-0583     Document Type: Article

References (44)

1. Francis RM, Selby PL (1997) Osteomalacia. Baillieres Clin Endocrinol Metab 11: 145-163.
2. Elidrissy AT (2016) The Return of Congenital Rickets, Are We Missing Occult Cases? Calcif Tissue Int 99: 227-236.
3. Munns CF, Shaw N, Kiely M, Specker BL, Thacher TD, et al. (2016) Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J Clin Endocrinol Metab 101: 394-415.
4. Malloy PJ, Feldman D (2010) Genetic disorders and defects in vitamin d action. Endocrinol Metab Clin North Am 39: 333-346.
5. Goldsweig BK, Carpenter TO (2015) Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis. Curr Osteoporos Rep 13: 88-97.
6. Hughes MR, Malloy PJ, Kieback DG, Kesterson RA, Pike JW, et al. (1988) Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 242: 1702-1705.
7. Malloy PJ, Tasic V, Taha D, Tutunculer F, Ying GS, et al. (2014) Vitamin D receptor mutations in patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets. Mol Genet Metab 111: 33-40.
8. Haussler MR (1986) Vitamin D receptors: nature and function. Annu Rev Nutr 6: 527-562.
9. Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, et al. (2008) Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 29: 726-776.
10. Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G (2016) Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol Rev 96: 365-408.
11. 3-induced transrepression by vitamin D receptor through E-box-type elements in the human parathyroid hormone gene promoter. Mol Endocrinol 21: 334-342.
12. 3. Biochem Biophys Res Commun 249: 11-16.
13. Malloy PJ, Feldman D (2011) The role of vitamin D receptor mutations in the development of alopecia. Mol Cell Endocrinol 347: 90-96.
14. Marx SJ, Bliziotes MM, Nanes M (1986) Analysis of the relation between alopecia and resistance to 1,25-dihy-droxyvitamin D. Clin Endocrinol (Oxf) 25: 373-381.
15. Li YC, Amling M, Pirro AE, Priemel M, Meuse J, et al. (1998) Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 139: 4391-4396.
16. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Sato K, et al. (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960.
17. 3-resistant rickets. J Clin Endocrinol Metab 82: 3892-3894.
18. Zhu W, Malloy PJ, Delvin E, Chabot G, Feldman D (1998) Hereditary 1,25-dihydroxyvitamin D-resistant rickets due to an opal mutation causing premature termination of the vitamin D receptor. J Bone Miner Res 13: 259-264.
19. Zhou Y, Wang J, Malloy PJ, Dolezel Z, Feldman D (2009) Compound heterozygous mutations in the vitamin D receptor in a patient with hereditary 1,25-dihy-droxyvitamin D-resistant rickets with alopecia. J Bone Miner Res 24: 643-651.
20. Amling M, Priemel M, Holzmann T, Chapin K, Rueger JM, et al. (1999) Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 140: 4982-4987.
21. Hoenderop JG, Nilius B, Bindels RJ (2005) Calcium absorption across epithelia. Physiol Rev 85: 373-422.
22. Tamura M, Isojima T, Kawashima M, Yoshida H, Yamamoto K, et al. (2015) Detection of Hereditary 1,25-Hydroxyvitamin D-Resistant Rickets Caused by Uniparental Disomy of Chromosome 12 Using Genome-Wide Single Nucleotide Polymorphism Array. PLoS One 10: e0131157.
23. Li YC, Bolt MJ, Cao LP, Sitrin MD (2001) Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism. Am J Physiol Endocrinol Metab 281: E558-564.
24. Friedman PA (2000) Mechanisms of renal calcium transport. Exp Nephrol 8: 343-350.
25. 3 resistant rickets in seven related families. J Clin Invest 86: 2071-2079.
26. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, et al. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357.
27. Takeda S, Yoshizawa T, Nagai Y, Yamato H, Fukumoto S, et al. (1999) Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice. Endocrinology 140: 1005-1008.
28. Sakai Y, Demay MB (2000) Evaluation of keratinocyte proliferation and differentiation in vitamin D receptor knockout mice. Endocrinology 141: 2043-2049.
29. Dardenne O, Prud’homme J, Arabian A, Glorieux FH, St-Arnaud R (2001) Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 142: 3135-3141.
30. Panda DK, Miao D, Tremblay ML, Siois J, Farookhi R, et al. (2001) Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci U S A 98: 7498-7503.
31. Lo Celso C, Prowse DM, Watt FM (2004) Transient activation of beta-catenin signalling in adult mouse epidermis is sufficient to induce new hair follicles but continuous activation is required to maintain hair follicle tumours. Development 131: 1787-1799.
32. Shimada T, Yamazaki Y, Takahashi M, hasegawa H, Urakawa I, et al. (2005) Vitamin D receptor-indepen-dent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289: 1088-1095.
33. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE (2005) Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 36: 971-977.
34. 3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289: G1036-1042.
35. 3 acts predominately in mature osteoblasts under conditions of high extracellular phosphate to increase fibroblast growth factor 23 production in vitro. J Endocrinol 206: 279-286.
36. 3 and phosphorus in vivo. J Biol Chem 280: 2543-2549.
37. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, et al. (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568.
38. Hesse M, Frohlich LF, Zeitz U, Lanske B, Erben RG (2007) Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol 26: 75-84.
39. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, et al. (2002) 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110: 229-238.
40. 3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 74: 170-179.
41. Simpson RU, Hershey SH, Nibbelink KA (2007) Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 103: 521-524.
42. Tiosano D, Schwartz Y, Braver Y, Hadash A, Gepstein V, et al. (2011) The renin-angiotensin system, blood pressure, and heart structure in patients with hereditary vitamin D-resistance rickets (HVDDR). J Bone Miner Res 26: 2252-2260.
43. Costa JL, Eijk PP, van de Wiel MA, ten Berge D, Schmitt F, et al. (2009) Anti-proliferative action of vitamin D in MCF7 is still active after siRNA-VDR knockdown. BMC Genomics 10: 499.
44. 3-1alpha-hydroxylase gene promoter. Proc Natl Acad Sci U S A 95: 1387-1391.